Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2012-01-17 Board/Management Inform…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Alan Raffensperger appointed Chief Operating Officer
Board/Management Information Classification · 98% confidence The document is a short press release dated January 17, 2012, announcing the appointment of Alan Raffensperger as the new Chief Operating Officer (COO). This announcement details changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' specifically covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report, an earnings release, or a proxy statement, but a specific personnel announcement.
2012-01-17 English
Sobi tecknar licensavtal för ny behandling inom neonatalområdet med Only For Children Pharmaceuticals
Capital/Financing Update Classification · 95% confidence The document is a press release dated January 13, 2012, announcing a specific corporate event: Sobi signing a global license agreement with Only For Children Pharmaceuticals regarding a new drug formulation. This announcement details a transaction (licensing deal, upfront payment, milestones, royalties) which falls under corporate financing or strategic activity. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). Since it details a significant agreement involving future payments and commercialization rights, it best fits the 'Capital/Financing Update' category (CAP) as it relates to structuring future capital deployment and revenue streams, or potentially a general 'Regulatory Filing' (RNS) if no better fit exists. However, given the focus on a major licensing deal involving financial terms, CAP is the most specific fit among the provided options, although M&A Activity (TAR) is sometimes used for major deals, this is a licensing agreement, not a merger or takeover. Given the options, 'CAP' (Capital/Financing Update) covers significant strategic financial agreements like this licensing deal. The document length is short (4250 chars) and it is a direct announcement, not a report itself, but it is a specific announcement type, not just a generic 'Report Publication Announcement' (RPA). Therefore, CAP is the most appropriate classification for a major licensing/financing agreement.
2012-01-13 Swedish
Sobi signs global licensing agreement for novel neonatology treatment from Only for Children Pharmaceuticals
Regulatory Filings Classification · 95% confidence The document is a press release dated January 13, 2012, announcing a specific corporate event: Sobi signing a global licensing agreement with Only for Children Pharmaceuticals regarding a neonatology treatment. This type of announcement, detailing strategic partnerships, licensing deals, and associated financial terms (upfront payments, milestones, royalties), is characteristic of corporate news releases that fall outside the scope of standard periodic financial reports (10-K, IR) or specific regulatory filings. Since it is a strategic business development announcement, it does not fit perfectly into the defined categories like ER (Earnings Release) or CAP (Capital/Financing Update, which usually implies raising debt/equity). However, it is a significant corporate action announcement. Given the options, this is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of material information, or potentially a general announcement that doesn't fit the highly specific financial/governance codes. Since it is a press release announcing a material business event, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as it is not a transcript, presentation, or formal financial report.
2012-01-13 English
Rättelse av uppgift i tidigare pressmeddelande
Regulatory Filings Classification · 95% confidence The document is a short press release dated December 1, 2011, titled "Rättelse av uppgift i tidigare pressmeddelande" (Correction of information in a previous press release). It corrects a specific financial metric (gross margin) from a prior announcement about a Capital Markets Day. Since it is a brief, specific announcement correcting data, and not a full report (like 10-K or IR), nor a standard earnings release (ER) which usually contains full period results, it fits best as a general regulatory announcement or a specific update. Given the content is a correction to a prior announcement, and it doesn't fit perfectly into the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal, market-sensitive communication.
2011-12-01 Swedish
Correction of previous press release
Earnings Release Classification · 99% confidence The document is titled 'Correction of previous press release' and corrects a specific financial metric (gross margin) from a prior announcement. It contains financial data tables and is dated, indicating a formal update. Since it is a correction to a press release, it is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is a specific, non-standard regulatory update correcting factual data. Given the options, this type of specific, factual correction that doesn't fit into major categories like DIRS, DIV, or CAP is best classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure correcting prior information. FY 2011
2011-12-01 English
Sobi har kapitalmarknadsdag
Earnings Release Classification · 99% confidence The document is dated November 29, 2011, and is titled "Sobi har kapitalmarknadsdag" (Sobi has Capital Markets Day). It details the program, including presentations by the CEO and CFO, covering business review, financial updates, and late-stage clinical projects (neonatology and hemophilia). It provides specific financial metrics (revenue, margins for product areas) and discusses upcoming impairment charges for Q4 2011. A Capital Markets Day presentation is a detailed event designed to give investors an in-depth look at the company's strategy, operations, and pipeline, which aligns perfectly with the definition of an Investor Presentation (IP). While it contains financial updates, its primary purpose is a strategic/operational deep dive presented at a specific investor event, making IP the most accurate classification over a standard Earnings Release (ER) or Interim Report (IR). FY 2011
2011-11-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.